PCLAF and type 2 diabetes mellitus: Decreased HDL-associated PAF-AH (H-PAF-AH) activities, increased apoB-containing lipoprotein-associated PAF-AH (apoB-PAF-AH) activities and/or the ratio of apoB-PAF-AH to total or H-PAF-AH activity are associated with cardiovascular diseases [14], type 2 diabetes [17], gestational diabetes mellitus [13], pre-eclampsia [18], and polycystic ovary syndrome [19, 20] and might be markers for chronic inflammation in these patients.